SHC · Sotera Health Co
$18.49
-0.11 (-0.59%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$5.23B
Shares
285.37M
Volume · Sep 30
2.03M
Avg daily vol (3M)
2.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.49
Open$18.68
Day$18.39–18.76
52W close$13.13–19.57
Avg vol 30d2.0M
Short int12.3M · 4.3% float · 7.3d
Short vol42%
Last earningsAug 6, 2026
DataNov 2020–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.22B
Trailing 12 months
Net income (TTM)
$163.48M
Trailing 12 months
Revenue growth YoY
+9.2%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
32.6
Trailing earnings · reciprocal yield 3.1%
FCF yield
2.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$1.78B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.8%
Year over year · more shares
Price change (1Y)
+18.1%
Trailing year
Short interest
4.3%
Latest settlement · 7.3 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Sotera Health raised its full-year 2026 outlook, with net revenues constant currency growth now guided to 5.25%-6.75% and Adjusted EBITDA growth to 5.75%-7.25%, while achieving its 3.0x net leverage target but still facing material EO litigation exposure.
Bullish
- + Raised full-year 2026 net revenues outlook to 5.25%-6.75% constant currency growth and Adjusted EBITDA growth to 5.75%-7.25%.
- + Achieved 3.0x net leverage ratio, hitting long-term target range with approximately $950 million in liquidity.
- + Sterigenics delivered 7.0% constant currency revenue growth with 53 bps segment income margin expansion.
- + Term loan repricing saved approximately $3.5 million in annual interest expense, with 2026 interest expense guidance improved to $135 million-$142 million.
- + Adjusted EPS improved to $0.26 in Q2, up 30% versus prior year, with full-year outlook raised to $0.95-$1.01.
Bearish
- − California EO litigation trials expected in January and April 2027, with ongoing Georgia appellate process.
- − Nelson Labs segment income declined 0.6% on a constant currency basis with segment income margin pressured by higher costs.
- − Foreign currency expected to be a slight headwind in Q3 2026.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+9%
above
Price vs 50-day avg
−1%
below
RSI (14)
47
neutral
MACD trend
Negative
52-week position
83%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
+21%
trailing
YTD return
+5%
this year
Relative strength
+9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +60 funds added
Insider flow
Distributing
Net -$24.0M over 90 days · 100% sells
Short interest
Rising
4.30% of float · ▲ +2.6% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
320 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
+6%
Y/Y
Gross margin
55%
expanding
EPS growth
+69%
Y/Y
Free cash flow
$149.2M
Valuation
P/E 32.2
below peers
Balance sheet
$1.8B
net debt
Quant / Vol
risk profile
Volatility
29%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
2.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 6, 2026
full-year 2026
Constant currency revenue growth
Non-GAAP
Initiated
5.25% – 6.75%
Constant currency adjusted EBITDA growth
Non-GAAP
Initiated
5.75% – 7.25%
2026
Total company revenue
$1.24B – $1.25B
prior FY $1.16B
midpoint +7.0% Y/Y
Adjusted EBITDA
Non-GAAP
$634M – $643M
Interest expense
$135M – $142M
Effective tax rate applicable to adjusted net income
Non-GAAP
27% – 28%
Adjusted EPS
Non-GAAP
$0.95 – $1.01
Capital expenditures
$200M – $225M
Total company pricing
3% – 4%
full year
Total company pricing improvement
3% – 4%
within the year
Total company improvement of pricing
3% – 4%
Guided vs delivered
· last 2 settled
Net revenues
2023
guided $1.04B – $1.06B
$1.05B
In line
Total revenues
full year 2021
guided $920M – $930M
$931.48M
Beat +0.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+9%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
83%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $19 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +60 funds added
Insider flow
Distributing
Net -$24.0M over 90 days · 100% sells
Short interest
Rising
4.30% of float · ▲ +2.6% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
320 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13
Now $18 · 83%
Range high $20
vs 200-day avg +9%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings per share - Basic non-GAAP | $0.44 | Six Months Ended June 30, 2026 | — |
| Adjusted earnings per share - Diluted non-GAAP | $0.44 | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $621.62M | Twelve Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Adjusted Net Income 276.64M
+143.35M Interest expense, net
+102.45M Depreciation
+99.19M Income tax provision applicable to Adjusted Net Income
= Adjusted EBITDA 621.62M
|
|||
| Adjusted EBITDA Margin non-GAAP | 51.1% | Twelve Months Ended June 30, 2026 | — |
| Adjusted EPS non-GAAP | $0.26 | Q2 2026 | — |
| available liquidity | 950M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SHC
this stock
Sotera Health Co
|
$5.23B | +4.8% | +5.7% | 32.2 | 4.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +16.5% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$155.42B | -3.2% | +8.5% | 39.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +80.4% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +26.6% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SHC | +1.1% | -1.0% | +21.0% | -2.2% | +4.8% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +1.8% | -1.1% | +8.8% | -1.6% | -7.0% |
Key facts
CIK
1822479
CUSIP
83601L102
13F (30d)
10 filings
10 filers
Visit website
Investor relations